Citadel Advisors
ERNA icon

Citadel Advisors’s Eterna Therapeutics ERNA Stock Holding History

Citadel Advisors’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$100K Buy
15,104
+13,781
+1,042% +$97.9K ﹤0.01% 12700
2026
Q1 		$6.58K Buy
+1,323
New +$21.1K ﹤0.01% 12796
2025
Q2 		– Sell
-175
Closed -$11.7K – 13199
2025
Q1 		$11.7K Buy
+175
New +$21.6K ﹤0.01% 13478
2024
Q2 		– Sell
-27
Closed -$24.1K – 14539
2024
Q1 		$24.1K Buy
+27
New +$18.6K ﹤0.01% 12873
2022
Q4 		– Sell
-7
Closed -$13K – 14986
2022
Q3 		$13K Sell
7
-21
-75% -$72.4K ﹤0.01% 12197
2022
Q2 		$107K Buy
28
+5
+22% +$35.9K ﹤0.01% 11348
2022
Q1 		$349K Buy
23
+7
+44% +$133K ﹤0.01% 10241
2021
Q4 		$490K Buy
16
+14
+700% +$761K ﹤0.01% 9745
2021
Q3 		$142K Buy
+2
New +$173K ﹤0.01% 12441
2021
Q2 		– Sell
-3
Closed -$432K – 13846
2021
Q1 		$85K Buy
3
+2
+200% +$108K ﹤0.01% 12597
2020
Q4 		$32K Buy
+1
New +$30.4K ﹤0.01% 10698
2020
Q1 		– Sell
-1
Closed -$38K – 9723
2019
Q4 		$38K Buy
+1
New +$42.6K ﹤0.01% 8818
2019
Q3 		– Sell
-1
Closed -$59K – 9303
2019
Q2 		$59K Buy
+1
New +$52.4K ﹤0.01% 8677
2018
Q4 		– Sell
-2
Closed -$110K – 9268
2018
Q3 		$110K Buy
+2
New +$144K ﹤0.01% 8536
2016
Q1 		– Hold
0
– -$2K – 7078
2015
Q4 		– Hold
0
– – – 8574
2015
Q3 		– Hold
0
– – – 8092
2015
Q2 		– Hold
0
– – – 8538
2015
Q1 		– Hold
0
– -$18K – 8603
2014
Q4 		– Hold
0
– – – 7890
2014
Q3 		– Hold
0
– – – 7750
2013
Q3 		– Hold
0
– -$12K – 6767
2013
Q2 		– Hold
0
– – – 6191

Other funds holding ERNA

Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Citadel Advisors's ERNA Position: Q2 2026 in Review

Citadel Advisors increased its Eterna Therapeutics (ERNA) stake by 1,042% in Q2 2026, buying an estimated $97.9K and bringing the position to 15,104 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #12700.

Citadel Advisors first reported a position in ERNA in Q3 2018 and has held it in 14 quarters since. The position peaked at $490K in Q4 2021. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Citadel Advisors held 15,104 shares of Eterna Therapeutics worth $100K as of Q2 2026.
  • Citadel Advisors bought 13,781 Eterna Therapeutics shares in Q2 2026, an estimated $97.9K.
  • Eterna Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12700 holding.
  • Citadel Advisors first reported a position in Eterna Therapeutics in Q3 2018 and has held it in 14 quarters since.
  • Citadel Advisors's Eterna Therapeutics position peaked at $490K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.